Metsera Inc. $MTSR Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC grew its position in Metsera Inc. (NASDAQ:MTSR) by 7.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 466,955 shares of the company’s stock after acquiring an additional 32,308 shares during the period. Geode Capital Management LLC’s holdings in Metsera were worth $13,287,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in MTSR. Strs Ohio purchased a new position in Metsera during the first quarter valued at $76,000. KLP Kapitalforvaltning AS acquired a new position in shares of Metsera during the 2nd quarter worth approximately $122,000. Corebridge Financial Inc. acquired a new position in Metsera during the first quarter worth $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Metsera in the first quarter valued at about $248,000. Finally, MetLife Investment Management LLC purchased a new stake in shares of Metsera in the 1st quarter valued at approximately $254,000.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MTSR. Wall Street Zen upgraded Metsera from a “sell” rating to a “hold” rating in a report on Wednesday, October 1st. Wells Fargo & Company downgraded shares of Metsera from an “overweight” rating to an “equal weight” rating and set a $54.00 price target for the company. in a research note on Tuesday, September 30th. Leerink Partners reissued a “market perform” rating and set a $57.00 price objective (down from $77.00) on shares of Metsera in a research report on Wednesday, September 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Metsera in a report on Wednesday, September 3rd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Metsera in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Metsera presently has an average rating of “Hold” and an average price target of $55.75.

Metsera Stock Down 0.4%

Shares of MTSR stock opened at $70.50 on Tuesday. Metsera Inc. has a 52-week low of $12.30 and a 52-week high of $83.86. The stock’s 50-day moving average price is $60.89 and its 200 day moving average price is $42.81. The stock has a market capitalization of $7.42 billion and a PE ratio of -11.16.

Metsera (NASDAQ:MTSR) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.55).

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.